BY ENHANCING AND IMPROVING THE EFFICIENCY OF THESE PROCESSES , BOTH EVERYDAY HEALTHCARE AND CRITICAL CARE DEPARTMENTS CAN REDUCE DELAYS IN TREATMENT AND OPTIMISE RESOURCE ALLOCATION .
H E A L T H I N S I G H T S
The process of drug development has traditionally been lengthy and resource intensive . In 2021 the Pharmaceutical Research and Manufacturers of America reported it takes an average of 10 – 15 years to develop a new medicine at a significant cost .
BY ENHANCING AND IMPROVING THE EFFICIENCY OF THESE PROCESSES , BOTH EVERYDAY HEALTHCARE AND CRITICAL CARE DEPARTMENTS CAN REDUCE DELAYS IN TREATMENT AND OPTIMISE RESOURCE ALLOCATION .
AI algorithms have the capability to learn and analyse datasets of drug compounds faster , more cost-effectively and with greater precision . Harnessing AI-Machine Learning enables researchers to identify potential compounds faster , more cost-effectively and with greater precision . Major pharmaceutical companies including Pfizer are investing in AI for this exact purpose .
There is also an immense opportunity to repurpose existing drugs with improved efficiency . By utilising AI , clinicians can sort through large databases of existing drugs and match up interactions of compounds with differing medical conditions – meaning they can identify existing regulatoryapproved drugs that may be able to tackle conditions not previously treated by the drug . Overall , this considerably shortens development time , meaning treatments can
18 www . intelligenthealth . tech